

Study Design and Reported Outcomes by Publication

	N (Fuse patients)	Follow-up	Design	VAS-SI Joint Pain	SF-12 PCS	SF-12 MCS	SF-36 PCS	SF-36 MCS	EQ-5D	Roland-Morris Disability	ODI	Patient Satisfaction
1- Rudolf 2012	50	Mean 40 mo	Retro	●								●
2- Sachs 2013	40	12 mo	Retro	●								●
3- Cummings 2013	18	12 mo	Retro	●	●	●						●
4- Smith 2013	114	24 mo	Retro	●								●
5- Gaetani 2013	10	Mean 10 mo	Retro	●					●	●		●
6- Schroeder 2013	6	Mean 10 mo	Retro	●						●		●
7- Ledonio 2014 (a)	22	Mean 15 mo	Retro	●						●		●
8- Ledonio 2014 (b)	17	Median 15 mo	Retro	●						●		●
9- Sachs 2014	144	12 mo	Retro	●								●
10- Rudolf 2014	17	60 mo	Retro	●								●
11- Vanaclocha 2014	24	Mean 23 mo	Retro	●						●		●
12- Bornemann 2016	24	24 mo	Retro	●						●		●
13- Vanaclocha 2017	27	Out to 72 mo	Retro	●						●		●
14- Rainov 2019	160	12 mo	Retro	●						●		●
15- Duhon 2016	172	24 mo	Prospective	●	●	●	●	●	●	●	●	●
16- Polly 2016	102	24 mo	RCT	●	●	●	●	●	●	●	●	●
17- Dengler 2019	52	24 mo	RCT	●						●	●	●
18- Patel 2019	28	6 mo	Prospective	●						●	●	●
19- Whang 2019	93	60 mo	Prospective	●						●	●	●

Retro = Retrospective; RCT = Randomized Controlled Trial



References

- Rudolf L. Sacroiliac Joint Arthrodesis-MIS Technique with Titanium Implants: Report of the First 50 Patients and Outcomes. *Open Orthop J.* 2012;6:495-502. DOI: 10.2174/1874325001206010495.
- Sachs D, et al. Minimally Invasive Sacroiliac Joint Fusion: One-Year Outcomes in 40 Patients. *Adv Orthop.* 2013;2013:536128. DOI: 10.1155/2013/536128.
- Cummings J Jr, et al. Minimally Invasive Sacroiliac Joint Fusion: One-Year Outcomes in 18 Patients. *Ann Surg Innov Res.* 2013;7:12. DOI: 10.1186/1750-1164-7-12.
- Smith AG, et al. Open Versus Minimally Invasive Sacroiliac Joint Fusion: A Multi-center Comparison of Perioperative Measures and Clinical Outcomes. *Ann Surg Innov Res.* 20213;7:14. DOI: 10.1186/1750-1164-7-14.
- Gaetani P, et al. Percutaneous Arthrodesis of Sacro-iliac Joint: A Pilot Study. *J Neurosurg Sci.* 2013;57:297-301.
- Schroeder JE, et al. Early Results of Sacro-iliac Joint Fixation Following Long Fusion to the Sacrum in Adult Spine Deformity. *HSS J.* 2013;10:30-5. DOI: 10.1007/s11420-013-9374-4.
- Ledonio CG, et al. Minimally Invasive Versus Open Sacroiliac Joint Fusion: Are They Similarly Safe and Effective? *Clin Orthop Relat Res.* 2014;472:1831-8. DOI: 10.1007/s11999-014-3499-8.
- Ledonio CG, et al. Comparative Effectiveness of Open Versus Minimally Invasive Sacroiliac Joint Fusion. *Med Devices (Auckl).* 2014;7:187-93. DOI: 10.2147/MDER.S60370.
- Sachs D, et al. One-year Outcomes After Minimally Invasive Sacroiliac Joint Fusion with a Series of Triangular Implants: A Multicenter, Patient-level Analysis. *Med Devices (Auckl).* 2014;7:299-304. DOI: 10.2147/MDER.S56491.
- Rudolf L, et al. Five-Year Clinical and Radiographic Outcomes After Minimally Invasive Sacroiliac Joint Fusion Using Triangular Implants. *Open Orthop J.* 2014;8:375-83. DOI: 10.2174/1874325001408010375.
- Vanaclocha-Vanaclocha V, et al. Minimally Invasive Sacroiliac Joint Arthrodesis: Experience in a Prospective Series with 24 Patients. *J Spine.* 2017;3:185. DOI: 10.4172/2165-7939.1000185.
- Bornemann R, et al. 2-year clinical results of patients with sacroiliac joint syndrome treated by arthrodesis using a triangular implant system. *Technol Health Care.* 2016;24(5):647-53. DOI: 10.3233/THC-161272.
- Vanaclocha V, et al. Minimally Invasive Sacroiliac Joint Fusion, Radiofrequency Denervation and Conservative Management for Sacroiliac Joint Pain: Six Year Comparative Study. *Neurosurgery.* 2018 Jan 1;82(1):48-55. [Epub 2017 Apr 20]. DOI: 10.1093/neuros/nyx185.
- Rainov NG, et al. Triangular titanium implants for sacroiliac joint fusion. *Eur Spine J.* 2019;28(4):727-34. [Epub 2018 Dec 18]. DOI: 10.1007/s00586-018-5860-1.
- Duhon BS, et al. Triangular Titanium Implants for Minimally Invasive Sacroiliac Joint Fusion: 2-Year Follow-Up from a Prospective Multicenter Trial. *Int J Spine Surg.* 2016;10:Article 13. DOI: 10.14444/3013.
- Polly DW et al., Two-Year Outcomes from a Randomized Controlled Trial of Minimally Invasive Sacroiliac Joint Fusion vs. Non-Surgical Management for Sacroiliac Joint Dysfunction. *Int J Spine Surg.* 2016;10:Article 28. DOI: 10.14444/3028.
- Dengler JD, et al. Randomized Trial of Sacroiliac Joint Fusion vs. Conservative Management for Chronic Low Back Pain Attributed to the Sacroiliac Joint. *J Bone Joint Surg Am.* 2019;101(5):400-11. DOI: 10.2106/JBJS.18.00022.
- Patel V, et al. Minimally Invasive Lateral Transiliac Sacroiliac Joint Fusion Using 3D-Printed Triangular Titanium Implants. *Med Devices (Auckl).* 2019;12:203-14. DOI: 10.2147/MDER.S205812.
- Whang PG, et al. Long-Term Prospective Clinical And Radiographic Outcomes After Minimally Invasive Lateral Transiliac Sacroiliac Joint Fusion Using Triangular Titanium Implants. *Med Devices (Auckl).* 2019;12:411-422. DOI: 10.2147/MDER.S219862.
- Copay AG, et al. Minimum Clinically Important Difference in Lumbar Spine Surgery Patients: A Choice of Methods Using the Oswestry Disability Index, Medical Outcomes Study questionnaire Short Form 36, and Pain Scales. *Spine J.* 2008;8:968-74.
- Glassman SD, et al. Defining Substantial Clinical Benefit Following Lumbar Spine Arthrodesis. *J Bone Joint Surg.* 2008;90:1839-47.

The iFuse Implant System® Difference  
**CLINICAL EVIDENCE**  
 February 2020



- |   |  |  |  |   |
|---|--|--|--|---|
| <p><b>SI-BONE, Inc. - Global HQ</b><br/>                 471 El Camino Real, Suite 101<br/>                 Santa Clara, CA 95050 USA<br/>                 t 408.207.0700<br/>                 f 408.557.8312<br/>                 info@si-bone.com</p> | <p><b>SI-BONE S.r.l. - European HQ</b><br/>                 Via Postcastello, 6<br/>                 21013 Gallarate (VA), Italy t +39<br/>                 0331 1561179<br/>                 f +39 0331 1561180<br/>                 infoeurope@SI-BONE.com</p> | <p><b>SI-BONE Deutschland GmbH</b><br/>                 Soldnerstraße 11<br/>                 D - 68219 Mannheim, Germany<br/>                 t +49 (621) 976860 00<br/>                 f +49 (621) 976860 99<br/>                 infodeutschland@si-bone.com</p> | <p><b>SI-BONE UK Ltd</b><br/>                 Unit 7b St James Business Park,<br/>                 Knaresborough, North Yorkshire,<br/>                 HG5 8QB, UK<br/>                 t +44 1423 860025<br/>                 infouk@si-bone.com</p> | <p><b>SI-BONE France</b><br/>                 6 rue des Merisiers<br/>                 FR-68920 Wettolsheim les Erlen, France<br/>                 t +33 9 73 79 03 92<br/>                 f +33 9 70 19 01 32<br/>                 france@si-bone.com</p> |
|---|--|--|--|---|


A list of additional published studies is available at [www.si-bone.com/results](http://www.si-bone.com/results)  
 One or more of the individuals named herein may be a past or present SI-BONE employee, paid consultant, investor, clinical trial investigator, or grant recipient.  
 For information about the indications and intended use, visit [www.si-bone.com](http://www.si-bone.com). There are potential risks associated with the iFuse Implant System. It may not be appropriate for all patients and all patients may not benefit. Rx Only. For information about the risks, visit [www.si-bone.com/risks](http://www.si-bone.com/risks)  
 SI-BONE, and iFuse Implant System are registered trademarks of SI-BONE, Inc. ©2020 SI-BONE, Inc. All rights reserved. Patents. [www.si-bone.com](http://www.si-bone.com)

**OUS Providers**  
 8809.110419


Consistent positive clinical outcomes supported by multiple studies, multiple outcomes & multiple time-points

All patients were treated for SI joint disruption or degenerative sacroiliitis.

## Rapid and Sustained Pain Relief – VAS SI Joint Pain



## Reduction in Disability – Oswestry Disability Index



## Improvement in Quality of Life

Measurement		Improvement Baseline to Follow-up		p-value
		Mean	Percent	
Whang 2019 <sup>19</sup> Prospective, 60 mo follow-up (n=93)	EQ-5D TTO	+0.29	64.4%	<0.0001
Patel 2019 <sup>18</sup> Prospective, 6 mo follow-up (n=28)	EQ-5D TTO	+0.26	54.2%	<0.0001
Dengler 2019 <sup>17</sup> RCT, 24 mo follow-up (n=52)	EQ-5D TTO	+0.39	111.4%	<0.0001
Polly 2016 <sup>16</sup> RCT, 24 mo follow-up (n=102)	SF-36 PCS	+11.2	37.1%	<0.0001
	SF-36 MCS	+8.2	19.1%	<0.0001
	EQ-5D TTO	+0.28	63.6%	<0.0001
Duhon 2016 <sup>15</sup> Prospective, 24 mo follow-up (n=172)	SF-36 PCS	+8.9	28.1%	<0.0001
	SF-36 MCS	+10.1	26.2%	<0.0001
	EQ-5D TTO	+0.27	62.8%	<0.0001
Gaetani 2013 <sup>5</sup> 10 mo mean follow-up (n=10)	Roland-Morris Disability	-14.6	83.0%	<0.001
Cummings 2013 <sup>3</sup> 12 mo follow-up (n=18)	SF-12 PCS	+11.2	34.7%	<0.005
	SF-12 MCS	+20.4	54.0%	<0.001

- Statistically significant improvement
- Consistent improvement across multiple Quality of Life measures

SF-12 ..... Short Form-12 Questionnaire  
 SF-36 ..... Short Form-36 Questionnaire  
 PCS ..... Physical Component Summary  
 MCS ..... Mental Component Summary  
 EQ-5D ..... EuroQoL-5 Dimension Questionnaire (5-question broad quality-of-life measure that can be combined into a single index)  
 TTO ..... Time Trade-off (0 to 1 scale, represents the time trade-off utility of current health)

## High Patient Satisfaction

